| QLi5 Therapeutics–Qurient: investment, 202001 founding as joint venture of Qurient Co Ltd + MPG + LDC + Robert Huber |
2020-01-16 |
| QLi5 Therapeutics–SEVERAL: investment, 202001 founding as joint venture of Qurient Co Ltd + MPG + LDC + Robert Huber |
2020-01-16 |
| Biograil–High-Tech Gründerfonds: investment, 202001 seed financing round totalling €3m (potentially up to €5m) incl lead investor HTGF |
2020-01-15 |
| Biograil–SEVERAL: investment, 202001 seed financing round €3m (potentially up to €5m) led by HTGF |
2020-01-15 |
| Danaher–Sophia Genetics: genomic technologies, 202001– collab ww expansion IDT NGS enrichment products with Sophia Genetics DDM for clinical research |
2020-01-15 |
| Lunaphore–Alpana Ventures: investment, 202001 financing round Series C totalling CHF23m incl existing + co-investor Alpana Ventures |
2020-01-15 |
| Lunaphore–Occident: investment, 202001 financing round Series C totalling CHF23m incl existing + co-investor Occident |
2020-01-15 |
| Lunaphore–PHC: investment, 202001 financing round Series C totalling CHF23m incl new + lead investor PHC Holdings Corp |
2020-01-15 |
| Lunaphore–Redalpine: investment, 202001 financing round Series C totalling CHF23m incl existing + co-investor Redalpine Venture Partners |
2020-01-15 |
| Lunaphore–SEVERAL: investment, 202001 financing round Series C CHF23m led by PHC Holdings Corp |
2020-01-15 |
| Temedica–Gruner + Jahr: investment, 202001 financing round Series B totalling €17m incl existing + co-investor G+J Digital Ventures |
2020-01-14 |
| Temedica–MIG Fonds: investment, 202001 financing round Series B totalling €17m incl co-lead investor MIG Funds |
2020-01-14 |
| Temedica–PERSON: investment, 202001 financing round Series B totalling €17m incl existing + co-investor Bernd Wendeln |
2020-01-14 |
| Temedica–Salvia: investment, 202001 financing round Series B totalling €17m incl co-lead investor Salvia |
2020-01-14 |
| Temedica–SEVERAL: investment, 202001 financing round Series B €17m led by MIG Funds + Santo VC + Salvia |
2020-01-14 |
| Temedica–Strüngmann Group: investment, 202001 financing round Series B totalling €17m incl co-lead investor Santo Venture Capital |
2020-01-14 |
| Amgen–Qiagen: molecular companion diagnostics, 202002– collab developm KRAS G12C CDx for AMG 510 in NSCLC |
2020-01-13 |
| Andrew Alliance–Waters: investment, 202001 acquisition by existent investor Waters |
2020-01-13 |
| Daiichi Sankyo–ERS Genomics: CRISPR technology, 202001– license ww excl €na for internal RnD |
2020-01-13 |
| Illumina–Roche: genomic cancer testing, 202001–201412 collab €na strategic alliance non-excl for NGS-based cancer testing for IVD + CDx |
2020-01-13 |
| Incyte–MorphoSys: tafasitamab, 202001– collab + ww excl license incl US co-commercialisation $750m upfront + $1.1b milestones |
2020-01-13 |
| MorphoSys–Incyte: investment, 202001 equity investment $150m in new ADSs at premium to share price as part of tafasitamab collab/license agreement |
2020-01-13 |
| NBE Therapeutics–Boehringer: investment, 202001 financing round Series C totalling $22m incl existing + co-lead investor BIVF |
2020-01-10 |
| NBE Therapeutics–OTHER: investment, 202001 financing round Series C USD22m incl all existing private shareholders |
2020-01-10 |
| NBE Therapeutics–PPF Group: investment, 202001 financing round Series C totalling $22m incl existing + co-lead investor PPF Group |
2020-01-10 |
| NBE Therapeutics–SEVERAL: investment, 202001 financing round Series C $22m led by existing investors BIVF + PPF Group wih all private investors |
2020-01-10 |
| Alderaan Biotechnology–SEVERAL: investment, 202001 financing round Series A €18.5m with Advent France Biotechnology + Medicxi |
2020-01-09 |
| Bayer–Evotec: drug discovery services, 201001–202412 collab expansion women’s health €16.5m upfront + research cost + milestones >€330m drugs for PCOS |
2020-01-09 |
| Bayer–Exscientia: AI-based drug discovery, 202001–202312 collab identification lead structures for drugs to treat cardiovascular diseases + cancers |
2020-01-09 |
| Cunesoft–Phlexglobal: investment, 202001 acquisition of Cunesoft GmbH by Phlexglobal |
2020-01-08 |
| Eyevensys–Bellevue: investment, 202001 financing round Series B totalling $30m incl new + co-investor Pureos Bioventures |
2020-01-08 |
| Eyevensys–Boehringer: investment, 202001 financing round Series B totalling $30m incl existing + lead investor Boehringer Ingelheim Venture Fund |
2020-01-08 |
| Eyevensys–SEVERAL: investment, 202001 financing round Series B $30m led by Boehringer Ingelheim Venture Fund |
2020-01-08 |
| Immunic–Daiichi Sankyo: IMU-856, 202001– license excl ww €na option exercised by Immunic AG |
2020-01-08 |
| Riemser–Esteve: investment, 202001– acquisition €na of Riemser from Ardian by Esteve |
2020-01-08 |
| Wellington Partners–MC Services: public relations, 202001 service existent by MC Services |
2020-01-08 |
| Boehringer–PhoreMost: drug discovery services, 202001– collab €na multi-project target discovery using Siteseeker platform |
2020-01-07 |
| CytomX Therapeutics–Genedata: bioinformatics, 202001– supply license for Genedata Bioprocess platform to CytomX Therapeutics |
2020-01-07 |
| MiNA Therapeutics–Trophic Communications: public relations, 202001 service existent by Trophic Communications |
2020-01-07 |
| VectivBio–Cowen: investment, 202001 1st financing round totalling $35m incl Cowen Healthcare Investors |
2020-01-07 |
| VectivBio–France (govt): investment, 202001 1st financing round totalling $35m incl Bpifrance + Inserm Transfer Initiative |
2020-01-07 |
| VectivBio–Novo Group: investment, 202001 1st financing round totalling $35m incl Novo Holdings |
2020-01-07 |
| VectivBio–OrbiMed: investment, 202001 1st financing round totalling $35m incl OrbiMed |
2020-01-07 |
| VectivBio–SEVERAL: investment, 202001 1st financing round $35m with Versant Ventures + Orbimed + Novo Holdings + Bpifrance et al. |
2020-01-07 |
| VectivBio–Tekla Capital: investment, 202001 1st financing round totalling $35m incl Tekla Healthcare Investors |
2020-01-07 |
| VectivBio–Versant Ventures: investment, 202001 1st financing round totalling $35m incl Versant Ventures |
2020-01-07 |
| VectivBio–WPP: public relations, 202001 service existent by Glover Park Group |
2020-01-07 |
| Velabs Therapeutics–Alytas Therapeutics: therapeutic antibodies, 202001– license excl for developm + commercialisation of Abs in field of senescence |
2020-01-07 |
| Bruker–Adeptrix: MS-based immunoassays, 202101– collab developm BAMS assays on Bruker MALDI-MS systems |
2020-01-06 |
| Bayer–Daré Bioscience: contraceptives, 202001– license excl for US for hormone-free monthly vagial contraceptive |
2020-01-01 |
| Innerspace–High-Tech Gründerfonds: investment, 2020 seed financing round incl investor HTGF |
2020-01-01 |
| Innerspace–MAD Ventures: investment, 2020 seed financing round incl investor MAD Ventures GmbH |
2020-01-01 |
| Innerspace–SEVERAL: investment, 2020 seed financing round with MAD Ventures + HTGF |
2020-01-01 |
| KLIFO–Gilde Investment: investment, 202105 acquisition of majority share in KLFIO A/S by Gilde Healthcare |
2020-01-01 |
| MediServ–KLIFO: investment, 2020 acquisition of MediServ by KLIFO A/S |
2020-01-01 |
| Tecan–Labforward: laboratory software, 2020– collab integration of Tecan detection devices with Labfolder LIMS |
2020-01-01 |
| TherVacB project–EU (govt): grant, 202001–202412 Horizon 2020 grant €10.4m for development of therapeutic Hepatitis B vaccine |
2020-01-01 |
| Vaderis Therapeutics–Medicxi: investment, 2020 Series A financing CHF18m from Medicxi |
2020-01-01 |
| Aeovian Pharmaceuticals–Evotec: investment, 201912 investment existent Evotec owns 5.83% of voting rights |
2019-12-31 |
| Autobahn Labs–Evotec: investment, 201912 investment existent Evotec owns 33.33% of voting rights |
2019-12-31 |
| Blacksmith Medicines–Evotec: investment, 201912 investment existent Evotec owns 15.09% of voting rights |
2019-12-31 |
| Breakpoint Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 48.6% of voting rights |
2019-12-31 |
| Carrick Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 4.29% of voting rights |
2019-12-31 |
| Celmatix–Evotec: investment, 201912 investment existent Evotec owns 25.02% of voting rights |
2019-12-31 |
| Eternygen–Evotec: investment, 201912 investment existent Evotec owns 24.97% of voting rights |
2019-12-31 |
| Exscientia–Evotec: investment, 201912 investment existent Evotec owns 23.21% of voting rights |
2019-12-31 |
| Fibrocor Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 16% of voting rights of Fibrocor LLP |
2019-12-31 |
| Forge Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 15.09% of voting rights |
2019-12-31 |
| FSHD Unlimited Coop–Evotec: investment, 201912 investment existent Evotec owns 21.12% of voting rights |
2019-12-31 |
| Immunitas Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 6.44% of voting rights |
2019-12-31 |
| Topas Therapeutics–Evotec: investment, 201912 investment existent Evotec owns 28.44% of voting rights |
2019-12-31 |
| Vico Therapeutics–Bellevue: investment, 2019Q4–202007 financing round Series A totalling €27m incl co-investor Pureos Bioventures |
2019-12-31 |
| Vico Therapeutics–Eurazeo: investment, 2019Q4–202007 financing round Series A totalling €27m incl co-investor Idinvest Partners |
2019-12-31 |
| Provecs–NONE: investment, 201912–202001 bankruptcy AG Hamburg 67g IN 290/19 insolvency + dissolution Provecs Medical GmbH |
2019-12-30 |
| Roche–Sarepta: delandistrogene moxeparvovec-rokl, 201912– license excl ww outside US $750m cash + $400m equity upfront + $1.7b milestones for SRP-9001 |
2019-12-23 |
| Nabriva–Sam Brown: public relations, 201912 service existent by Sam Brown Inc |
2019-12-20 |
| Nabriva–SEVERAL: investment, 201912 registered direct offering $20m with 13.8m pairs ordinary share + warrant at $1.45/pair to institutional investors |
2019-12-20 |
| Nagi Bioscience–NEST Pension Fund: investment, 201912 seed financing round totalling CHF1.8m incl investor NEST Pension Fund |
2019-12-20 |
| Nagi Bioscience–OTHER: investment, 201912 seed financing round totalling CHF1.8m incl private investors from CH + US |
2019-12-20 |
| Nagi Bioscience–SEVERAL: investment, 201912 seed financing round CHF1.8m with investiere + ZKB + NEST Pension Fund + private investors from CH + US |
2019-12-20 |
| Nagi Bioscience–Verve Capital Partners: investment, 201912 seed financing round totalling CHF1.8m incl investor investiere |
2019-12-20 |
| Nagi Bioscience–Zürcher Kantonalbank: investment, 201912 seed financing round totalling CHF1.8m incl investor ZKB |
2019-12-20 |
| CureVac–Genmab: investment, 201912 equity investment €20m by Genmab as part of strategic alliance |
2019-12-19 |
| Genmab–CureVac: mRNA-based antibody therapeutics, 201912– collab research + license agreem 5y $10m upfront using CureVac mRNA + Genmab Ab technologies |
2019-12-19 |
| Kinnate Biopharma–Nextech: investment, 201912 financing round Series B totalling $74.5m incl new investor Nextech Invest Ltd |
2019-12-19 |
| Kinnate Biopharma–SEVERAL: investment, 201912 financing round Series B $74.5m from OrbiMed + Nextech Invest + Vida Ventures + Foresite + Eshelman |
2019-12-19 |
| Promega–Merck (DE): CRISPR technology, 201912– license to CRISPR IP io from Merck to Promega to develop CRISPR-edited cell lines |
2019-12-19 |
| BC Platforms–SEVERAL: investment, 201912 financing round Series C $15m led by Iqvia + incl Debiopharm Innovation Fund + Tesi |
2019-12-18 |
| Hitachi–Showa Denko: investment, 201912–202004 acquisition of Hitachi Chemical for JPY964b ($8.8b) |
2019-12-18 |
| Novartis–Voluntis: digital therapeutics, 201912–collab developm digital therapeutics using Theraxium Oncology platform for breast cancer |
2019-12-18 |
| BioNtech–EU (govt): credit, 201912– EIB/EFSI loan €50m to support cancer therapies RnD |
2019-12-17 |
| Cellestia Biotech–SEVERAL: investment, 201912 financing round Series B CHF20m from FC Capital + PPF Group + Partners Investment + private investors |
2019-12-17 |
| Resistell–SEVERAL: investment, 201912 financing round Series A CHF3.5m |
2019-12-17 |
| 3SBio–Numab: antibody cancer drug, 201912– collab developm + commercialisation with Sunshine Guojian for multi-specific Abs in Greater China |
2019-12-12 |
| Numab–3SBio: investment, 201912–202003 financing round Series B totalling CHF22m incl CHF15m from new investor 3SBio/Sunshine Guojian |
2019-12-12 |
| Numab–Eisai: investment, 201912–202003 financing round Series B totalling CHF22m incl new + co-investor Eisai Co Ltd |
2019-12-12 |
| Numab–Mitsubishi: investment, 201912–202003 financing round Series B totalling CHF22m incl new + co-investor Mitsubishi UFJ Capital Co Ltd |
2019-12-12 |
| Numab–PERSON: investment, 201912–202003 financing round Series B totalling CHF22m incl new + co-investor Daniel Vasella |
2019-12-12 |
| Numab–SEVERAL: investment, 201912–202003 financing round Series B CHF22m incl €15m from new investor 3SBio/Sunhine Guojian |
2019-12-12 |
| Abcalis–Germany (govt): grant, 201912 EXIST research transfer grant for founding from BMWi (plus ESF grant) |
2019-12-10 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 ... 22 23 24 ... 42 43 44 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
